Abstract:e16045 Background: Currently, the real-world evidence is not available to support the practice of induction immunochemotherapy (iIC) plus conversion surgery for initially-unresectable esophageal squamous cell carcinoma (ESCC). This study aimed to evaluate the feasibility, safety and effectiveness of conversion surgery following iIC for advanced ESCC in a real-world scenario. Methods: In this multi-center, single-arm, real-world study (NCT04822103), patients who had unresectable cT4b ESCC tumors with evident involvement of the adjacent organs (aorta, trachea, or bronchus) or had multi-station, bulky lymphadenopathy were enrolled across eight medical centers in China. All patients received programmed death receptor-1 (PD-1) inhibitor plus chemotherapy every three weeks. Radiologcal assessment was performed for patients who completed at least two cycles of immunochemotherapy. In general, patients with significant relief of cancer-related clinical symptoms and radiological complete response/partial response disease were deemed surgical candidates. The primary endpoints were the objective response rate (ORR) per RECIST version 1.1 and safety profile per CTCAE version 5.0. Results: Between Nov 2019 and June 2021, 155 patients were enrolled in the final analysis. The numbers of patients with pre-treatment clinical stage III, and IVA were 21 (13.5%) and 134 (86.5%), respectively. Upon the completion of preoperative treatment, 6 (3.9%) patients achieved radiological complete response (CR), 92 (59.4%) achieved partial response (PR), and 45 (29.0%) achieved stable disease (SD), yielding an ORR and DCR of 63.3% and 92.3%, respectively. Esophagectomy was then offered to 116 patients who were considered suitable for surgery, yeilding a conversion rate of 74.8%. 109 out of 116 patients achieved R0 resection. Pathological complete response (pCR) of the primary tumor was observed in 26 (22.4%) patients, with 25 (21.6%) of them achieving pCR in both primary tumor and metastatic lymph nodes. Most patients (111/116, 95.7%) had a downstaging in tumor invasion depth. However, downstaging of nodal metastasis was observed in 48 (48/116, 41%) patients. Thirteen patients (13/116, 11.2%) had progressive nodal response. Among the treated patients, 69.0% (107/155) patients experienced at least one treatment-related adverse event (TRAEs), while 29% (49/155) had grade three or higher (G ≥ 3) TRAEs, including leukopenia (20/155, 12.9%), neutropenia (18/155, 11.6%), rash (12/155, 7.7%), diarrhea (6/155, 3.9%), and infection (6/155, 3.9%). Conclusions: We demonstrated that conversion surgery following immunochemotherapy is feasible, safe and effective for initially-unresectable ESCC patients. Further larger-scale studies are needed to establish the standard-of-care use of iIC in the preoperative settings for initially-unresectable ESCC patients.

Defining Conversion Therapy for Esophageal Squamous Cell Carcinoma

[Advancements and Controversies in Conversion Therapy for Biliary Tract Malignant Tumors with Insufficient Future Liver Remnant].

The efficacy and safety of conversion therapy after initial systemic chemotherapy in advanced esophageal cancer with distant metastases: A multicenter retrospective observational study.

Safety and Efficacy of Conversion Therapy After Systemic Chemotherapy in Advanced Esophageal Cancer with Distant Metastases: A Multicenter Retrospective Observational Study

Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)

International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO‐GC‐1)

Current Status and Perspectives of Conversion Therapy for Advanced Gastric Cancer

Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities

Conversion therapy for unresectable hepatocellular carcinoma: Advances and challenges

Conversion surgery for esophageal and esophagogastric junction cancer

[Progress and Reflection of Conversion Therapy for Locally Advanced Pancreatic Cancer].

Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

[A Surgery-Oriented Classification in Conversion Therapy of Gastric Cancer].

Conversion Therapy of Hepatocellular Carcinoma: Some Pivotal Issues to Be Resolved

[Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma(2024 edition)]

Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma—A Real-World Multicenter Study (RICE-Retro)

Conversion therapy with chemoimmunotherapy induced pCR in a stage IV lung squamous cell carcinoma patient harboring EGFR exon 20 insertion

Consensus of Chinese expert on neoadjuvant and conversion therapies for hepatocellular carcinoma: 2023 update

Conversion surgery following immuno-chemotherapy in initially-unresectable esophageal squamous cell carcinoma: A real-world multicenter study.

Conversion Surgery for Tislelizumab Combined Chemotherapy for T4a/N3 Esophageal Squamous Cell Carcinoma (ESCC): A Prospective, Single-Arm, Phase II Study.

Clinical Impact of Conversion Surgery After Induction Therapy for Esophageal Cancer with Synchronous Distant Metastasis: A Multi-institutional Retrospective Study